Market Overview:
The global traumatic brain injury therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of traumatic brain injuries, rising awareness about available treatments, and technological advancements in the field of traumatic brain injury therapeutics. The global traumatic brain injury therapeutics market is segmented on the basis of type, application, and region. On the basis of application, the market is divided into local TBI (treatment administered at or near site where injury occurred), open TBI (treatment administered after skull has been opened), closed TBI (treatment administered without opening skull), diffuse TBI (injury that affects more than one area of brain) and primary TBI (the first insult leading to subsequent insults).S.
Product Definition:
Traumatic Brain Injury Therapeutics is the use of treatments and interventions to help people who have experienced a traumatic brain injury. Traumatic brain injuries can cause a range of problems, from minor concussions to severe damage that can lead to death. Therapeutic treatments can help reduce symptoms and improve quality of life for people with traumatic brain injuries.
Acetylcholinesterase Inhibitors:
The most commonly used drug is donepezil which has been approved by the Food and Drug Administration (FDA) for treatment-resistant Alzheimer's disease, but it is also used to treat traumatic brain injury (TBI).
Erythropoietin:
Erythropoietin (EPO) is a glycoprotein hormone responsible for stimulating the bone marrow to produce red blood cells. It is produced in the kidney, liver, and gut of vertebrates. In humans, it is a cytokine involved in regulating the rate of red blood cell production and its life span. Increasing awareness about erythropoietin as a treatment option for brain injury has led to several clinical trials being conducted over recent years with promising results.
Application Insights:
Primary TBI segment dominated the global traumatic brain injury therapeutics market in 2017. This is owing to the rising incidence of TBIs, which accounts for a major share of overall traumatic brain injuries. According to data published by the Centers for Disease Control and Prevention (CDC), an estimated 1,000,000 people are hospitalized every year due to TBIs in U.S., which comprises about 2% of all hospitalizations due to injuries across the globe.
The localTBI segment held a significant share in 2017 as well as it is anticipated to grow at a lucrative rate over the forecast period owingto its low cost and easy accessibility compared with other treatment options such as surgery or craniotomy procedures for treating LTCIs.
Regional Analysis:
North America dominated the global traumatic brain injury therapeutics market in 2017. This can be attributed to the presence of key players, high R&D investment by these companies and availability of effective treatment methods for TBI. In addition, increasing road accidents and rising incidence of Alzheimer’s disease are also contributing towards growth in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as growing medical tourism industry, increase in healthcare expenditure by government & private sectors due to rise in awareness about brain injuries caused during accidents and sports injuries along with favorable reimbursement policies implemented by governments for treating TBI cases.
The key players operating in this region are BrainGate Inc., Medtronic plc., Cerebral Sciences International Inc.
Growth Factors:
- Increasing incidence of traumatic brain injuries (TBI) due to road accidents, sports injuries, and violence
- Growing awareness about the symptoms and long-term effects of TBI
- Rising demand for better treatment options for TBI patients
- increasing investment in research and development of new TBI therapies
- growing number of clinical trials for novel TBI therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Traumatic Brain Injury Therapeutics Market Research Report
By Type
Acetylcholinesterase Inhibitors, Erythropoietin, Growth Hormone, Stem Cells, Others
By Application
Local TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI, Others
By Companies
SFC Fluidics LLC, Banayan Biomarkers Inc., BHR Pharma LLC, Cerora Inc., ElMindA Ltd., Grace Laboratories LLC, KeyNeurotek Pharmaceuticals AG, Luoxis Diagnostics, Neuro Assessment Systems, Neurovive Pharmaceuticals AB, Oxygen Biotherapeutics Inc., Phlogistix LLC, Neurohealing Pharmaceuticals, Neuren Pharmaceuticals Ltd., Remedy Pharmaceuticals Inc., Biodirection Inc., Brainscope Company Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Traumatic Brain Injury Therapeutics Market Report Segments:
The global Traumatic Brain Injury Therapeutics market is segmented on the basis of:
Types
Acetylcholinesterase Inhibitors, Erythropoietin, Growth Hormone, Stem Cells, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Local TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- SFC Fluidics LLC
- Banayan Biomarkers Inc.
- BHR Pharma LLC
- Cerora Inc.
- ElMindA Ltd.
- Grace Laboratories LLC
- KeyNeurotek Pharmaceuticals AG
- Luoxis Diagnostics
- Neuro Assessment Systems
- Neurovive Pharmaceuticals AB
- Oxygen Biotherapeutics Inc.
- Phlogistix LLC
- Neurohealing Pharmaceuticals
- Neuren Pharmaceuticals Ltd.
- Remedy Pharmaceuticals Inc.
- Biodirection Inc.
- Brainscope Company Inc.
- TEVA Pharmaceutical Industries Ltd.
- Vasopharm
Highlights of The Traumatic Brain Injury Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acetylcholinesterase Inhibitors
- Erythropoietin
- Growth Hormone
- Stem Cells
- Others
- By Application:
- Local TBI
- Open TBI
- Closed TBI
- Diffuse TBI
- Primary TBI
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Traumatic Brain Injury Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Traumatic brain injury therapeutics is the application of medical treatments to individuals with traumatic brain injuries. These treatments may include medications, surgery, and physical therapy.
Some of the major companies in the traumatic brain injury therapeutics market are SFC Fluidics LLC, Banayan Biomarkers Inc., BHR Pharma LLC, Cerora Inc., ElMindA Ltd., Grace Laboratories LLC, KeyNeurotek Pharmaceuticals AG, Luoxis Diagnostics, Neuro Assessment Systems, Neurovive Pharmaceuticals AB, Oxygen Biotherapeutics Inc., Phlogistix LLC, Neurohealing Pharmaceuticals, Neuren Pharmaceuticals Ltd., Remedy Pharmaceuticals Inc., Biodirection Inc., Brainscope Company Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm.
The traumatic brain injury therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Traumatic Brain Injury Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Traumatic Brain Injury Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Traumatic Brain Injury Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Traumatic Brain Injury Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Traumatic Brain Injury Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Traumatic Brain Injury Therapeutics Market Size and Y-o-Y Growth
4.5.2 Traumatic Brain Injury Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Traumatic Brain Injury Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Traumatic Brain Injury Therapeutics Market Size Forecast by Type
5.2.1 Acetylcholinesterase Inhibitors
5.2.2 Erythropoietin
5.2.3 Growth Hormone
5.2.4 Stem Cells
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Traumatic Brain Injury Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Traumatic Brain Injury Therapeutics Market Size Forecast by Applications
6.2.1 Local TBI
6.2.2 Open TBI
6.2.3 Closed TBI
6.2.4 Diffuse TBI
6.2.5 Primary TBI
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Traumatic Brain Injury Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Traumatic Brain Injury Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Traumatic Brain Injury Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Traumatic Brain Injury Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Traumatic Brain Injury Therapeutics Market Size Forecast by Type
9.6.1 Acetylcholinesterase Inhibitors
9.6.2 Erythropoietin
9.6.3 Growth Hormone
9.6.4 Stem Cells
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Traumatic Brain Injury Therapeutics Market Size Forecast by Applications
9.10.1 Local TBI
9.10.2 Open TBI
9.10.3 Closed TBI
9.10.4 Diffuse TBI
9.10.5 Primary TBI
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Traumatic Brain Injury Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Traumatic Brain Injury Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Traumatic Brain Injury Therapeutics Market Size Forecast by Type
10.6.1 Acetylcholinesterase Inhibitors
10.6.2 Erythropoietin
10.6.3 Growth Hormone
10.6.4 Stem Cells
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Traumatic Brain Injury Therapeutics Market Size Forecast by Applications
10.10.1 Local TBI
10.10.2 Open TBI
10.10.3 Closed TBI
10.10.4 Diffuse TBI
10.10.5 Primary TBI
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Traumatic Brain Injury Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Traumatic Brain Injury Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Traumatic Brain Injury Therapeutics Market Size Forecast by Type
11.6.1 Acetylcholinesterase Inhibitors
11.6.2 Erythropoietin
11.6.3 Growth Hormone
11.6.4 Stem Cells
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Traumatic Brain Injury Therapeutics Market Size Forecast by Applications
11.10.1 Local TBI
11.10.2 Open TBI
11.10.3 Closed TBI
11.10.4 Diffuse TBI
11.10.5 Primary TBI
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Traumatic Brain Injury Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Traumatic Brain Injury Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Traumatic Brain Injury Therapeutics Market Size Forecast by Type
12.6.1 Acetylcholinesterase Inhibitors
12.6.2 Erythropoietin
12.6.3 Growth Hormone
12.6.4 Stem Cells
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Traumatic Brain Injury Therapeutics Market Size Forecast by Applications
12.10.1 Local TBI
12.10.2 Open TBI
12.10.3 Closed TBI
12.10.4 Diffuse TBI
12.10.5 Primary TBI
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Traumatic Brain Injury Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Traumatic Brain Injury Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Traumatic Brain Injury Therapeutics Market Size Forecast by Type
13.6.1 Acetylcholinesterase Inhibitors
13.6.2 Erythropoietin
13.6.3 Growth Hormone
13.6.4 Stem Cells
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Traumatic Brain Injury Therapeutics Market Size Forecast by Applications
13.10.1 Local TBI
13.10.2 Open TBI
13.10.3 Closed TBI
13.10.4 Diffuse TBI
13.10.5 Primary TBI
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Traumatic Brain Injury Therapeutics Market: Competitive Dashboard
14.2 Global Traumatic Brain Injury Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 SFC Fluidics LLC
14.3.2 Banayan Biomarkers Inc.
14.3.3 BHR Pharma LLC
14.3.4 Cerora Inc.
14.3.5 ElMindA Ltd.
14.3.6 Grace Laboratories LLC
14.3.7 KeyNeurotek Pharmaceuticals AG
14.3.8 Luoxis Diagnostics
14.3.9 Neuro Assessment Systems
14.3.10 Neurovive Pharmaceuticals AB
14.3.11 Oxygen Biotherapeutics Inc.
14.3.12 Phlogistix LLC
14.3.13 Neurohealing Pharmaceuticals
14.3.14 Neuren Pharmaceuticals Ltd.
14.3.15 Remedy Pharmaceuticals Inc.
14.3.16 Biodirection Inc.
14.3.17 Brainscope Company Inc.
14.3.18 TEVA Pharmaceutical Industries Ltd.
14.3.19 Vasopharm
